GSK plc (GLAXF) shareholders

GLAXFOTCPharmaceutical PreparationsAlso trades as GSK

Financials through fiscal 2025, year ended Dec 31, 2025Score 9/30

$24.74+0.30 (+1.21%)

Close on Oct 19, 2026Market cap $106.83BP/E 13.3Yield –

Ownership

Who owns GSK's shares

Held by institutions

–

Shares held, 13F filers

Institutional holders

–

Net institutional buying

–

Insider trades, 12 months

0 buys · 0 sales

Open-market trades only

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

Holder	Shares	% of class	Filing	As of
BlackRock, Inc.	369,576,114	8.90%	13G (passive) amendment	Dec 31, 2024
Abigail P. Johnson Joint filing with FMR LLC (5.80%)	234,936,061	5.80%	13G (passive)	Mar 31, 2026
GSK plc	1,983,025	9.50%	13D (active) amendment	Nov 12, 2024

Short interest

Shares sold short and not yet bought back, as of Oct 15, 2026 (FINRA, reported twice a month)

Short % of shares outstanding

–

1M shares short

Days to cover

329.5

At 0M shares a day

Change since last report

+0.9%

From 1M shares

Short volume, 0 days

–

Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of GSK's stock actually held short. No settlement fails above the SEC's reporting threshold in the last 90 days.